Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T-cell-rich B-cell lymphoma

J Rodriguez1, W C Pugh, F Cabanillas

  • 1Department of Hematology, University of Texas, M.D. Anderson Cancer Center, Houston 77030.

Blood
|September 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Curability Potential of Low-Grade Follicular Lymphoma.

Clinical lymphoma, myeloma & leukemia·2025
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2007
Same author

A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.

Leukemia & lymphoma·2007
Same author

High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.

Annals of oncology : official journal of the European Society for Medical Oncology·2006

T-cell-rich B-cell lymphomas (BCL) show similar clinical features and outcomes to common B-cell large cell lymphomas. However, distinguishing T-cell-rich BCL is crucial for appropriate treatment, differentiating it from Hodgkin

Area of Science:

  • Hematopathology
  • Oncology
  • Immunology

Background:

  • T-cell-rich B-cell lymphomas (BCL) are a subtype of non-Hodgkin lymphoma.
  • Accurate diagnosis is essential for appropriate patient management and treatment strategies.

Purpose of the Study:

  • To determine if T-cell-rich BCL represents a distinct clinicopathological entity.
  • To compare the clinical features and outcomes of T-cell-rich BCL with classical B-cell large cell lymphoma.

Main Methods:

  • Analysis of 23 T-cell-rich BCL cases from the University of Texas M.D. Anderson Cancer Center (1988-1991).
  • Inclusion criteria required at least 50% T-cell phenotype in the tumor population.
  • Review of clinical data, including diagnosis, therapy, splenomegaly, Ann Arbor stage, lactate dehydrogenase (LDH) levels, age, sex, and beta 2-microglobulin.

Related Experiment Videos

Main Results:

  • 65% of cases were initially misdiagnosed (e.g., Hodgkin's disease, peripheral T-cell lymphoma).
  • Splenomegaly occurred in 35% of cases, a higher proportion than in classical BCL.
  • Clinical presentation, outcome, and most laboratory markers did not significantly differ from classical B-cell large cell lymphoma.

Conclusions:

  • T-cell-rich BCL does not appear to be a distinct clinicopathological entity based on clinical features and outcomes.
  • The T-cell-rich infiltrate can be an unstable parameter, varying at different disease sites or during relapse.
  • Accurate pathological distinction from other lymphoid malignancies like Hodgkin's disease and peripheral T-cell lymphoma is critical for guiding treatment decisions.